Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 8/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23757872 | 0.83 | GRM1 (0.58) | GRM1TDP1MEN1KMT2ANPC1 | |
| SCHEMBL3088453 | 0.82 | GRM1 (0.58) | GRM1TDP1 | |
| SCHEMBL8354874 | 0.82 | GRM1 (1.00) | GRM1NPC1RAB9AL3MBTL1 | |
| SCHEMBL16621408 | 0.81 | TDP1 (0.66) | GRM1TDP1MEN1KMT2ANPC1 | |
| SCHEMBL22110718 | 0.80 | TDP1 (0.64) | GRM1TDP1MEN1KMT2ANPC1 | |
| SCHEMBL4428208 | 0.79 | NPC1 (0.67) | GRM1TDP1MEN1KMT2ANPC1 | |
| SCHEMBL18423031 | 0.79 | TDP1 (0.62) | GRM1TDP1MEN1KMT2ANPC1 | |
| SCHEMBL22672667 | 0.79 | TDP1 (0.62) | GRM1TDP1MEN1KMT2ANPC1 | |
| SCHEMBL29151067 | 0.79 | TDP1 (0.62) | GRM1TDP1MEN1KMT2ANPC1 | |
| SCHEMBL13597686 | 0.78 | MEN1 (0.54) | GRM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066360-B | Quinoline-or isoquinoline-substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV | 2013-10-30 | — | — | CN | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| EP-2285800-B1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-16 | — | — | EP | disclosed |
| CN-102066360-A | Quinoline-or isoquinoline-substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV | 2011-05-18 | — | — | CN | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| EP-2285800-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009132000-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | P2RX7, P2RX1, P2RX3 | GRM1 590/4885TDP1 1606/4885MEN1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.